PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsEdrecolomab
Edrecolomab
Edrecolomab is an antibody pharmaceutical. It is currently being investigated in clinical studies. It is known to target epithelial cell adhesion molecule.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
alleviaunapproved drug other2025-02-27
choline c 11New Drug Application2024-12-17
zyrexalunapproved drug other2020-02-10
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01F: Monoclonal antibodies and antibody drug conjugates
L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
L01FX01: Edrecolomab
HCPCS
No data
Clinical
Clinical Trials
781 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sickle cell anemiaD000755EFO_0000697D57111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80313
CarcinomaD002277C80.011
Breast neoplasmsD001943EFO_0003869C5011
Triple negative breast neoplasmsD06472611
Invasive hydatidiform moleD002820D39.211
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD01517922
Pancreatic ductal carcinomaD02144122
Non-small-cell lung carcinomaD00228922
Lung neoplasmsD008175C34.9022
Colonic neoplasmsD003110C1822
Rectal neoplasmsD01200422
LeukemiaD007938C9511
Myeloid leukemia acuteD015470C92.011
Multiple myelomaD009101C90.011
LymphomaD008223C85.911
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.111
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameEdrecolomab
INNedrecolomab
Description
Edrecolomab (mouse mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108955
ChEBI ID
PubChem CID
DrugBankDB13375
UNII ID0KYI9U9FSJ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
EPCAM
EPCAM
Organism
Homo sapiens
Gene name
EPCAM
Gene synonyms
GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1
NCBI Gene ID
Protein name
epithelial cell adhesion molecule
Protein synonyms
Adenocarcinoma-associated antigen, CD326, Cell surface glycoprotein Trop-1, EGP, EGP314, Epithelial cell surface antigen, Epithelial glycoprotein, Epithelial glycoprotein 314, hEGP314, human epithelial glycoprotein-2, KS 1/4 antigen, KSA, Major gastrointestinal tumor-associated protein GA733-2, membrane component, chromosome 4, surface marker (35kD glycoprotein), trophoblast cell surface antigen 1, Tumor-associated calcium signal transducer 1
Uniprot ID
Mouse ortholog
Epcam (17075)
epithelial cell adhesion molecule (Q99JW5)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 295,462 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
14,053 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use